Daunorubicin Liposomal Dosage

Usual Adult Dose for Kaposi's Sarcoma

40 mg/m2 IV over a minimum of 30 to 60 minutes once every 2 weeks for as long as disease control can be maintained

Comments:

• The dosing presented here is manufacturer suggested. The dose should be adjusted for each individual patient.

Use: For the treatment of advanced HIV-related Kaposi's sarcoma

Renal Dose Adjustments

Limited clinical experience exists in treating renally impaired patients with this drug. Based on experience with the conventional formulation, the manufacturer recommends that the dose be reduced if serum creatinine is greater than 3 mg/dL (greater than 265 micromole/L): Administer 50% of the normal dose.

Liver Dose Adjustments

Limited clinical experience exists in treating hepatically impaired patients with this drug. Based on experience with the conventional formulation, the manufacturer recommends that the dose be reduced if serum bilirubin is elevated as follows:

• Serum bilirubin 1.2 to 3 mg/dL (20.3 to 50.8 micromole/L): Administer 75% of the normal dose.
• Serum bilirubin greater than 3 mg/dL (greater than 50.8 micromole/L): Administer 50% of the normal dose.

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients
• Pregnancy
• Breastfeeding

• Safety and efficacy have not been established in patients younger than 18 years.
• Safety and efficacy have not of established in patients older than 65 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Aseptic technique should be observed handling since no preservative or bacteriostatic agent is present in the product.
• Any unused product or waste material should be disposed of in accordance with local requirements. Procedures for proper handling and disposal of anticancer drugs should be followed.

Storage requirements:

• Store in the refrigerator at 2C to 8C.

Reconstitution/preparation techniques:

• This drug should be diluted with 5% dextrose for infusion before administration.

IV compatibility:

• This drug is only compatible with 5% dextrose for infusion.

General:

• The liposomal formulation of this drug is not interchangeable with the conventional formulation.

Monitoring:

• Renal function
• Hepatic function
• Cardiac function

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer